Sugi Predict

Sugi Predict / Targets / PIK3CB

PIK3CB

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform · P42338 · PIK3CB on Sugi Atlas →

235,035 patent compounds predicted against PIK3CB, 134,247 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7050 SCHEMBL7050 1.00 20/20
SCHEMBL7052 SCHEMBL7052 1.00 20/20
SCHEMBL7070 SCHEMBL7070 1.00 20/20
SCHEMBL7166 SCHEMBL7166 1.00 20/20
SCHEMBL7186 SCHEMBL7186 1.00 20/20
SCHEMBL7257 SCHEMBL7257 1.00 20/20
SCHEMBL7283 SCHEMBL7283 1.00 20/20
SCHEMBL7291 SCHEMBL7291 1.00 20/20
SCHEMBL7499 SCHEMBL7499 1.00 20/20
SCHEMBL7530 SCHEMBL7530 1.00 20/20
SCHEMBL7558 SCHEMBL7558 1.00 20/20
SCHEMBL7575 SCHEMBL7575 1.00 20/20
SCHEMBL7603 SCHEMBL7603 1.00 20/20
SCHEMBL7607 SCHEMBL7607 1.00 20/20
SCHEMBL7619 SCHEMBL7619 1.00 20/20
SCHEMBL7633 SCHEMBL7633 1.00 20/20
SCHEMBL7659 SCHEMBL7659 1.00 20/20
SCHEMBL7693 SCHEMBL7693 1.00 20/20
SCHEMBL7700 SCHEMBL7700 1.00 20/20
SCHEMBL7728 SCHEMBL7728 1.00 20/20

Clinical trials — most relevant to PIK3CB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial PHASE2/PHASE3UNKNOWN
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia PHASE2WITHDRAWN
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) PHASE2COMPLETED
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Paclitaxel and TAK-228 in Urothelial Carcinoma PHASE2UNKNOWN
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer PHASE1COMPLETED
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer PHASE1ACTIVE_NOT_RECRUITING
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma PHASE1COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome nanRECRUITING
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer nanWITHDRAWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
Exploring the Link Between Cancer Genetics and PPSP nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PIK3CB binder may also engage these)

ProteinNameSimilarity
Q8BTI9 — 1.000 Q8BTI9 →
A0A0G2K344 — 1.000 A0A0G2K344 →
Q9Z1L0 — 1.000 Q9Z1L0 →
PIK3CA Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 0.999 landscape →
P32871 — 0.999 P32871 →
P42337 — 0.998 P42337 →
O02697 — 0.995 O02697 →
Q9JHG7 — 0.994 Q9JHG7 →
P42348 — 0.991 P42348 →
PIK3CG Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform 0.991 landscape →
PIK3CD Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform 0.990 landscape →
Q5D891 — 0.989 Q5D891 →
Q6AZN6 — 0.989 Q6AZN6 →
PIK3C3 Phosphatidylinositol 3-kinase catalytic subunit type 3 0.988 landscape →
P42339 — 0.987 P42339 →
O88763 — 0.987 O88763 →
O35904 — 0.987 O35904 →
Q6PF93 — 0.987 Q6PF93 →
A6N6J5 — 0.984 A6N6J5 →
Q7Z392 — 0.984 Q7Z392 →
P42347 — 0.983 P42347 →
P50520 — 0.983 P50520 →
B2RXC1 — 0.983 B2RXC1 →
B4NBB0 — 0.982 B4NBB0 →
USP7 Ubiquitin carboxyl-terminal hydrolase 7 0.982 landscape →
DNM2 Dynamin-2 0.982 landscape →
Q86T65 — 0.982 Q86T65 →
Q008S8 — 0.982 Q008S8 →
G5EF51 — 0.982 G5EF51 →
Q5ZJM3 — 0.982 Q5ZJM3 →